COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA

Objective: to perform cost-effectiveness analysis of brentuximab vedotin (BV) in patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma (HL).Materials and methods. This study was performed in two parts in 2015. In the first part Markov model was built on the basis of the results of co...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Фармакоэкономика
المؤلفون الرئيسيون:	G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
التنسيق:	مقال
اللغة:	الروسية
منشور في:	IRBIS LLC 2016-04-01
الموضوعات:	brentuximab vedotin relapsed or refractory cd30-positive hodgkin’s lymphoma cost-effectiveness analysis chemotherapy radiotherapy autologous stem cell transplantation allogeneic stem cell transplantation
الوصول للمادة أونلاين:	https://www.pharmacoeconomics.ru/jour/article/view/131